Brazil Pharmaceutical Market Outlook 2018
Brazil is considered as one of the most lucrative healthcare markets, accounting for the highest healthcare expenditure in Latin America. It is the largest pharmaceutical market in Latin America and the fifth largest globally. Strong government support and high healthcare services demand are two of the major factors propelling the country’s pharmaceutical market. Drug makers are also keen to tap the Brazilian market because it is one of the most lucrative and fastest-growing pharma markets worldwide. Pharma companies such as Sanofi, Pfizer, Boehringer Ingelheim, Sun Pharma, GSK, etc., have been trying to expand their businesses in Latin America following acquisition of domestic manufactures.
The Brazilian Government has adopted several initiatives and implemented appropriate plans and policies that have resulted in the positive development of the country’s overall healthcare services and facilities. In our latest research study “Brazil Pharmaceutical Market Outlook 2018”, RNCOS’ analysts have identified the market dynamics of major pharmaceutical segments such as Generics, OTC and Prescription Drugs. Accordingly, a study has been conducted for their current market sizes and forecasts for the next five years. The Pharmaceutical market, which stood at US$ 26.89 Billion in 2013, is expected to grow at a CAGR of 14.5% during 2013-2018.
RNCOS’ analysis shows that the Over-the-Counter drug and Generic drug segments have been the fastest growing and are expected to surpass the branded medications market in the near future. Government support to encourage the domestic drug industry, rising healthcare expenditure, patent expiry, reduced taxations, high disposable incomes, etc., are few important drivers resulting in high growth in these segments. Further analysis includes current market statistics, key drivers stimulating each segment’s growth, and future outlook of the segments.
EMS Pharma, Hypermarcas, Ache Laboratories, Eurofarma are the top four domestic pharma companies, with EMS Pharma and Ache Laboratories leading the Generics and Prescription Drug segments respectively. These companies contributed around 50% of the domestic pharmaceutical market in 2013. Among the foreign players, Sanofi, Novartis and Roche have been generating a significant amount of revenue from the Brazilian market since the last three years.
The report, covers all the necessary aspects of the Brazilian Pharmaceutical market, providing an in-depth research and prudent analysis of the key segments. The topics covered in the report include: Pharmaceutical Production, Prescription Segment, OTC Segment, Therapeutic Segment as well as Mergers and Acquisitions. The report also presents an insight into the current industry trends, key market drivers, and government initiatives to enable the clients understand the market structure and its growth during the forecasted period. The report also covers detailed information about active market players in the Brazil pharmaceutical industry, including domestic and foreign players.
The Brazilian Government has adopted several initiatives and implemented appropriate plans and policies that have resulted in the positive development of the country’s overall healthcare services and facilities. In our latest research study “Brazil Pharmaceutical Market Outlook 2018”, RNCOS’ analysts have identified the market dynamics of major pharmaceutical segments such as Generics, OTC and Prescription Drugs. Accordingly, a study has been conducted for their current market sizes and forecasts for the next five years. The Pharmaceutical market, which stood at US$ 26.89 Billion in 2013, is expected to grow at a CAGR of 14.5% during 2013-2018.
RNCOS’ analysis shows that the Over-the-Counter drug and Generic drug segments have been the fastest growing and are expected to surpass the branded medications market in the near future. Government support to encourage the domestic drug industry, rising healthcare expenditure, patent expiry, reduced taxations, high disposable incomes, etc., are few important drivers resulting in high growth in these segments. Further analysis includes current market statistics, key drivers stimulating each segment’s growth, and future outlook of the segments.
EMS Pharma, Hypermarcas, Ache Laboratories, Eurofarma are the top four domestic pharma companies, with EMS Pharma and Ache Laboratories leading the Generics and Prescription Drug segments respectively. These companies contributed around 50% of the domestic pharmaceutical market in 2013. Among the foreign players, Sanofi, Novartis and Roche have been generating a significant amount of revenue from the Brazilian market since the last three years.
The report, covers all the necessary aspects of the Brazilian Pharmaceutical market, providing an in-depth research and prudent analysis of the key segments. The topics covered in the report include: Pharmaceutical Production, Prescription Segment, OTC Segment, Therapeutic Segment as well as Mergers and Acquisitions. The report also presents an insight into the current industry trends, key market drivers, and government initiatives to enable the clients understand the market structure and its growth during the forecasted period. The report also covers detailed information about active market players in the Brazil pharmaceutical industry, including domestic and foreign players.
1. ANALYST VIEW
2. RESEARCH METHODOLOGY
3. MARKET DRIVERS
3.1 Public and Private Expenditure on Healthcare
3.2 Rising Number of Clinical Trials
3.3 Rising Disposable Income
3.4 Ageing Population
4. MARKET CHALLENGES
4.1 High Prices of Medications
4.2 Dependence on Imported Drugs
4.3 Stringent Drug Licensing and Regulatory Laws
4.4 High Tax Burden
5. PHARMACEUTICAL INDUSTRY OVERVIEW
6. MARKET SEGMENTATION
6.1 OTC Drug
6.1.1 Regulatory Framework
6.2 Generics
6.2.1 Regulatory Framework
6.3 Prescription Drug
6.3.1 Regulatory Framework
7. THERAPEUTIC SEGMENTS IN BRAZIL
7.1 Oncology
7.2 Infectious Diseases
7.3 Cardiovascular and Diabetes
7.4 CNS Diseases
8. MERGERS AND ACQUISITIONS (PREMIUM DEALS SINCE 2010)
9. COMPETITIVE LANDSCAPE
9.1 Share of Domestic Vs International Players
9.2 Overall Market Share Breakdown
10. KEY PLAYERS
10.1 EMS
10.2 Hypermarcas
10.3 Ache Laboratories
10.4 Eurofarma
10.5 Sanofi-Aventis
10.6 F. Hoffmann La Roche
10.7 Novartis
10.8 Pfizer
10.9 Merck Group
2. RESEARCH METHODOLOGY
3. MARKET DRIVERS
3.1 Public and Private Expenditure on Healthcare
3.2 Rising Number of Clinical Trials
3.3 Rising Disposable Income
3.4 Ageing Population
4. MARKET CHALLENGES
4.1 High Prices of Medications
4.2 Dependence on Imported Drugs
4.3 Stringent Drug Licensing and Regulatory Laws
4.4 High Tax Burden
5. PHARMACEUTICAL INDUSTRY OVERVIEW
6. MARKET SEGMENTATION
6.1 OTC Drug
6.1.1 Regulatory Framework
6.2 Generics
6.2.1 Regulatory Framework
6.3 Prescription Drug
6.3.1 Regulatory Framework
7. THERAPEUTIC SEGMENTS IN BRAZIL
7.1 Oncology
7.2 Infectious Diseases
7.3 Cardiovascular and Diabetes
7.4 CNS Diseases
8. MERGERS AND ACQUISITIONS (PREMIUM DEALS SINCE 2010)
9. COMPETITIVE LANDSCAPE
9.1 Share of Domestic Vs International Players
9.2 Overall Market Share Breakdown
10. KEY PLAYERS
10.1 EMS
10.2 Hypermarcas
10.3 Ache Laboratories
10.4 Eurofarma
10.5 Sanofi-Aventis
10.6 F. Hoffmann La Roche
10.7 Novartis
10.8 Pfizer
10.9 Merck Group
LIST OF FIGURES
Figure 3-1: Expenditure on Health (% of GDP), 2008-2013
Figure 3-2: Total Expenditure on Health per capita (PPP int.US$), 2008-2013
Figure 3-3: Share of Government and Private Expenditure (2012)
Figure 3-4: Government Expenditure on Health (% of total expenditure), 2008-2012
Figure 3-5: Private Expenditure on Health (% of total expenditure), 2008-2012
Figure 3-6: Number of Clinical Trials (2008-2014)
Figure 3-7: Annual Disposable Income (Million US$), 2010-2014
Figure 3-8: Disposable Income Brackets (%), 2012
Figure 3-9: Population above 65 Years (Million), 2008-2013
Figure 5-1: Share of Brazilian Pharmaceutical Market in Latin America (2013)
Figure 5-2: Pharmaceutical Production (Million US$), 2011-2013
Figure 5-3: Pharmaceutical Production Share by Use (2013)
Figure 5-4: Pharmaceutical Production by Use (Million US$), 2012 & 2013
Figure 5-5: Pharmaceutical Production by Ingredients (Million US$), 2012 & 2013
Figure 5-6: Pharmaceutical Production Share by Ingredients (2013)
Figure 5-7: Pharmaceutical Trade (Million US$), 2011-2013
Figure 5-8: Pharmaceutical Market (Billion US$), 2013-2018
Figure 5-9: Pharmaceutical Sales Volume (Billion Units), 2008-2013
Figure 6-1: Pharmaceutical Market Share by Segments (2013)
Figure 6-2: Pharmaceutical Market Share by Segments (2018)
Figure 6-3: OTC Drugs Market (Billion US$), 2013-2018
Figure 6-4: OTC Market Segmentation by Category (2013)
Figure 6-5: Generics Market (Billion US$), 2013-2018
Figure 6-6: Generics Drug Sales by Volume (Million Units), 2008-2013
Figure 6-7: Generics Drug Laboratories (2010-2013)
Figure 6-8: Generics Drug Market by Country of Origin (%), 2013
Figure 6-9: Number of Generics Drugs Registered by Company (2013)
Figure 6-10: Prescription Drugs Market Segmentation (2013)
Figure 6-11: Prescription Drugs Market (Billion US$), 2013-2018
Figure 7-1: Number of HIV Cases Registered ('000), 2005 & 2013
Figure 7-2: HIV Infection Rate in Adult Population (%), 2013 & 2030
Figure 7-3: Diabetic Patients in Age Group 20-79 Years (Million), 2013 & 2030
Figure 9-1: Share of Domestic and International Players (2013)
Figure 9-2: Market Share of Leading Players in Brazilian Pharmaceutical Market (2013)
Figure 10-1: Hypermarcas - Revenue Share by Business Segments (2013)
Figure 10-2: Ache Laboratories - Revenue Share by Business Segments (2013)
Figure 10-3: Sanofi-Aventis - Revenue by Business Segments (Million US$), 2012 & 2013
Figure 10-4: Sanofi-Aventis - Revenue Share by Geographical Regions (2013)
Figure 10-5: Sanofi-Aventis - Revenue Share by Different Regions in Emerging Market (2013)
Figure 10-6: Roche - Revenue Share by Business Segments (2013)
Figure 10-7: Roche - Revenue Share by Therapeutic Segments (2013)
Figure 10-8: Roche - Pharmaceutical Revenue Share by Geographical Regions (2013)
Figure 10-9: Novartis - Revenue Share by Business Segments (2013)
Figure 10-10: Novartis - Pharmaceutical Revenue Share by Geographical Regions (2013)
Figure 10-11: Pfizer - Revenue Share by Business Segments (2013)
Figure 10-12: Pfizer - Revenue Share by Geographical Regions (2013)
Figure 10-13: Merck Group - Revenue Share of Biopharmaceuticals by Geographic Regions (2013)
Figure 10-14: Merck Group - Revenue Share of OTC by Geographic Regions (2013)
Figure 3-1: Expenditure on Health (% of GDP), 2008-2013
Figure 3-2: Total Expenditure on Health per capita (PPP int.US$), 2008-2013
Figure 3-3: Share of Government and Private Expenditure (2012)
Figure 3-4: Government Expenditure on Health (% of total expenditure), 2008-2012
Figure 3-5: Private Expenditure on Health (% of total expenditure), 2008-2012
Figure 3-6: Number of Clinical Trials (2008-2014)
Figure 3-7: Annual Disposable Income (Million US$), 2010-2014
Figure 3-8: Disposable Income Brackets (%), 2012
Figure 3-9: Population above 65 Years (Million), 2008-2013
Figure 5-1: Share of Brazilian Pharmaceutical Market in Latin America (2013)
Figure 5-2: Pharmaceutical Production (Million US$), 2011-2013
Figure 5-3: Pharmaceutical Production Share by Use (2013)
Figure 5-4: Pharmaceutical Production by Use (Million US$), 2012 & 2013
Figure 5-5: Pharmaceutical Production by Ingredients (Million US$), 2012 & 2013
Figure 5-6: Pharmaceutical Production Share by Ingredients (2013)
Figure 5-7: Pharmaceutical Trade (Million US$), 2011-2013
Figure 5-8: Pharmaceutical Market (Billion US$), 2013-2018
Figure 5-9: Pharmaceutical Sales Volume (Billion Units), 2008-2013
Figure 6-1: Pharmaceutical Market Share by Segments (2013)
Figure 6-2: Pharmaceutical Market Share by Segments (2018)
Figure 6-3: OTC Drugs Market (Billion US$), 2013-2018
Figure 6-4: OTC Market Segmentation by Category (2013)
Figure 6-5: Generics Market (Billion US$), 2013-2018
Figure 6-6: Generics Drug Sales by Volume (Million Units), 2008-2013
Figure 6-7: Generics Drug Laboratories (2010-2013)
Figure 6-8: Generics Drug Market by Country of Origin (%), 2013
Figure 6-9: Number of Generics Drugs Registered by Company (2013)
Figure 6-10: Prescription Drugs Market Segmentation (2013)
Figure 6-11: Prescription Drugs Market (Billion US$), 2013-2018
Figure 7-1: Number of HIV Cases Registered ('000), 2005 & 2013
Figure 7-2: HIV Infection Rate in Adult Population (%), 2013 & 2030
Figure 7-3: Diabetic Patients in Age Group 20-79 Years (Million), 2013 & 2030
Figure 9-1: Share of Domestic and International Players (2013)
Figure 9-2: Market Share of Leading Players in Brazilian Pharmaceutical Market (2013)
Figure 10-1: Hypermarcas - Revenue Share by Business Segments (2013)
Figure 10-2: Ache Laboratories - Revenue Share by Business Segments (2013)
Figure 10-3: Sanofi-Aventis - Revenue by Business Segments (Million US$), 2012 & 2013
Figure 10-4: Sanofi-Aventis - Revenue Share by Geographical Regions (2013)
Figure 10-5: Sanofi-Aventis - Revenue Share by Different Regions in Emerging Market (2013)
Figure 10-6: Roche - Revenue Share by Business Segments (2013)
Figure 10-7: Roche - Revenue Share by Therapeutic Segments (2013)
Figure 10-8: Roche - Pharmaceutical Revenue Share by Geographical Regions (2013)
Figure 10-9: Novartis - Revenue Share by Business Segments (2013)
Figure 10-10: Novartis - Pharmaceutical Revenue Share by Geographical Regions (2013)
Figure 10-11: Pfizer - Revenue Share by Business Segments (2013)
Figure 10-12: Pfizer - Revenue Share by Geographical Regions (2013)
Figure 10-13: Merck Group - Revenue Share of Biopharmaceuticals by Geographic Regions (2013)
Figure 10-14: Merck Group - Revenue Share of OTC by Geographic Regions (2013)
LIST OF TABLES
Table 3-1: Household Disposable Income Brackets (‘000), 2012
Table 5-1: Ranking of Medications by Sales (2013)
Table 6-1: Number of Generics Drugs by Country (2013)
Table 7-1: Prevalence of Overweight and Obesity by Gender (%), 2013
Table 10-1: Hypermarcas - Revenue by Business Segments (Million US$), 2012 & 2013
Table 10-2: Ache Laboratories - Revenue by Business Segments (Million US$), 2012 & 2013
Table 10-3: Novartis - Revenue by Business Segments (Million US$), 2012 & 2013
Table 10-4: Pfizer - Revenue by Business Segments (Million US$), 2012 & 2013
Table 10-5: Merck Group - Revenue by Business Segments (Million US$), 2012 & 2013
Table 3-1: Household Disposable Income Brackets (‘000), 2012
Table 5-1: Ranking of Medications by Sales (2013)
Table 6-1: Number of Generics Drugs by Country (2013)
Table 7-1: Prevalence of Overweight and Obesity by Gender (%), 2013
Table 10-1: Hypermarcas - Revenue by Business Segments (Million US$), 2012 & 2013
Table 10-2: Ache Laboratories - Revenue by Business Segments (Million US$), 2012 & 2013
Table 10-3: Novartis - Revenue by Business Segments (Million US$), 2012 & 2013
Table 10-4: Pfizer - Revenue by Business Segments (Million US$), 2012 & 2013
Table 10-5: Merck Group - Revenue by Business Segments (Million US$), 2012 & 2013
